ADMA Biologics, Inc. (ADMA)Healthcare | Biotechnology | Ramsey, United States | NasdaqGM
9.34 USD
-0.14
(-1.477%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.52 +0.18 (1.927%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:34 a.m. EDT
The investment case here is defined by a stark disconnect between the company's operational recovery and the legal overhang weighing on the stock. Fundamentally, the business has turned a corner; after five years of decline, the last two years saw explosive growth (+352% and +1.7%), driven by a 16% revenue expansion and a robust 42% return on equity. The balance sheet is surprisingly healthy for a biotech, holding $5.6 billion in cash against debt, which provides a substantial safety net. However, the long-term rating remains neutral because the market is currently pricing in a severe discount due to the looming class-action lawsuit deadline in August 2026. This legal threat creates a 'value trap' dynamic where the stock is cheap not because the business is broken, but because investors fear a settlement or regulatory fallout that could erase the recent gains. Short-term, the stock is showing signs of life, trading above its 50-day average and seeing increased call volume at distant strikes, suggesting smart money is betting on the lawsuit being resolved without catastrophic damage. Yet, until the legal cloud lifts, the risk-reward profile remains skewed toward caution despite the impressive underlying fundamentals. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.115671 |
| AutoARIMA | 0.127150 |
| AutoETS | 0.127156 |
| AutoTheta | 0.140293 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 2.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.040 |
| Excess Kurtosis | 1.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 110.673 |
| Revenue per Share | 2.178 |
| Market Cap | 2,092,016,896 |
| Trailing P/E | 13.54 |
| Forward P/E | 9.51 |
| Beta | 0.77 |
| Profit Margins | 32.98% |
| Website | https://www.admabiologics.com |
As of Aug. 22, 2026, 2:34 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. Call Open Interest is heavily skewed toward out-of-the-money strikes (30 and 32), suggesting a speculative bet on a massive rally, while Put Open Interest clusters tightly around the current price (6-10 range), indicating a defensive floor. The massive volume spike at the 30 strike for January 2027 calls implies a 'lottery ticket' thesis, whereas the tight put wall suggests investors fear a drop back to the $6 level but are less concerned about a total collapse.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.44883722 |
| Address1 | 465 State Route 17 |
| All Time High | 25.67 |
| All Time Low | 1.01 |
| Ask | 11.52 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,684,080 |
| Average Daily Volume3 Month | 2,898,561 |
| Average Volume | 2,898,561 |
| Average Volume10Days | 1,684,080 |
| Beta | 0.768 |
| Bid | 6.44 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 1.811 |
| City | Ramsey |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.34 |
| Current Ratio | 6.972 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 9.51 |
| Day Low | 9.34 |
| Debt To Equity | 110.673 |
| Display Name | ADMA Biologics |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 224,192,992 |
| Ebitda Margins | 0.43764 |
| Enterprise To Ebitda | 195.544 |
| Enterprise To Revenue | 85.578 |
| Enterprise Value | 43,839,565,824 |
| Eps Current Year | 0.79667 |
| Eps Forward | 0.9825 |
| Eps Trailing Twelve Months | 0.69 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 201 478 5553 |
| Fifty Day Average | 9.0389 |
| Fifty Day Average Change | 0.30109978 |
| Fifty Day Average Change Percent | 0.03331155 |
| Fifty Two Week Change Percent | -44.88372 |
| Fifty Two Week High | 20.458 |
| Fifty Two Week High Change | -11.118 |
| Fifty Two Week High Change Percent | -0.5434549 |
| Fifty Two Week Low | 7.21 |
| Fifty Two Week Low Change | 2.13 |
| Fifty Two Week Low Change Percent | 0.29542303 |
| Fifty Two Week Range | 7.21 - 20.458 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,382,016,600,000 |
| Float Shares | 219,657,296 |
| Forward Eps | 0.9825 |
| Forward P E | 9.506361 |
| Free Cashflow | 54,755,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 640 |
| Fullday Change | -0.139999 |
| Fullday Change Percent | -1.47679 |
| Fullday Price | 9.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.64705 |
| Gross Profits | 331,468,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01969 |
| Held Percent Institutions | 0.93263 |
| Implied Shares Outstanding | 223,984,680 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. |
| Long Name | ADMA Biologics, Inc. |
| Market | us_market |
| Market Cap | 2,092,016,896 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_51119246 |
| Most Recent Quarter | 1,616,630,400 |
| Net Income To Common | 168,958,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,123,374,766 |
| Number Of Analyst Opinions | 5 |
| Open | 9.46 |
| Operating Cashflow | 136,720,000 |
| Operating Margins | -1.23389 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 201 478 5552 |
| Post Market Change | 0.1800003 |
| Post Market Change Percent | 1.927198 |
| Post Market Price | 9.52 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 9.48 |
| Price Eps Current Year | 11.723801 |
| Price Hint | 2 |
| Price To Book | 5.1573715 |
| Price To Sales Trailing12 Months | 4.083777 |
| Profit Margins | 0.32981998 |
| Quick Ratio | 3.62 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.139999 |
| Regular Market Change Percent | -1.47679 |
| Regular Market Day High | 9.51 |
| Regular Market Day Low | 9.34 |
| Regular Market Day Range | 9.34 - 9.51 |
| Regular Market Open | 9.46 |
| Regular Market Previous Close | 9.48 |
| Regular Market Price | 9.34 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,835,691 |
| Return On Assets | 0.2178 |
| Return On Equity | 0.41897 |
| Revenue Growth | 0.159 |
| Revenue Per Share | 2.178 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 223,984,680 |
| Shares Percent Shares Out | 0.1013 |
| Shares Short | 22,683,647 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 24,031,512 |
| Short Name | ADMA Biologics Inc |
| Short Percent Of Float | 0.1248 |
| Short Ratio | 8.53 |
| Source Interval | 15 |
| State | NJ |
| Symbol | ADMA |
| Target High Price | 21.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 17.0 |
| Total Cash | 55,921,152,000 |
| Total Cash Per Share | 249.665 |
| Total Debt | 97,668,702,208 |
| Total Revenue | 512,275,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.69 |
| Trailing P E | 13.536232 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.827325 |
| Two Hundred Day Average Change | -3.4873247 |
| Two Hundred Day Average Change Percent | -0.2718669 |
| Type Disp | Equity |
| Volume | 1,835,691 |
| Website | https://www.admabiologics.com |
| Zip | 7,446 |